



## Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting

May 11, 2020

*Presentations will showcase data on the potential of gene circuits to precisely target cancer and new preclinical data on SENTI-101*

**SOUTH SAN FRANCISCO, May 11, 2020** — Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, today announced upcoming oral and poster presentations at the 23rd Annual Meeting of the American Society for Gene and Cell Therapies (ASGCT), being held May 12-15, 2020 in a virtual format.

"We are excited about this opportunity to further showcase the potential of our gene circuit platform in oncology," said Tim Lu, M.D., Ph.D., CEO and cofounder of Senti Biosciences. "At ASGCT, we are presenting data on in vivo gene therapies, which are equipped with computer-like logic to target tumors in a highly specific manner. Additionally, we will highlight new preclinical data on SENTI-101, an allogeneic cell therapy genetically modified to express a potent combination of cytokines, which give us confidence in its therapeutic potential as we progress towards IND submission."

Details of the presentations are listed below:

### **ASGCT Annual Meeting, May 12-15, 2020**

**Title:** Tumor-Selective Gene Circuits Enable Highly Specific Localized Cancer Immunotherapy

**Abstract Number:** 17

**Oral Presentation Session:** Cancer — Targeted Gene and Cell Therapy

**Presentation Date and Time:** May 12, 10:45 a.m. - 11:00 a.m. EDT

**Presenter:** Russell Gordley, Ph.D.

**Title:** Phenotypic and Functional Characterization of Gene Circuit Modified Allogeneic Mesenchymal Stromal Cells (MSCs) for Solid Tumor Immunotherapy

**Abstract Number:** 783

**Poster Session:** Cancer — Targeted Gene and Cell Therapy

**Presentation Date and Time:** May 13, 5:30 p.m. - 6:30 p.m. EDT

**Presenter:** Dharini Iyer, Ph.D.

**Title:** SENTI-101, an Allogeneic Cell Product Expressing a Combination of Cytokines, Promotes Anti-Tumor Immunity in a Syngeneic Orthotopic Model of Pancreatic Ductal Adenocarcinoma

**Abstract Number:** 1180

**Poster Session:** Cancer — Targeted Gene and Cell Therapy

**Presentation Date and Time:** May 14, 5:30 p.m. - 6:30 p.m. EDT

**Presenter:** Ori Maller, Ph.D.

### **About Senti Biosciences**

Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti's mission is to outsmart complex diseases with more intelligent medicines that will transform people's lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.

Senti's product candidates address major challenges in cancer treatment. To overcome cancer immune evasion, Senti is building cell therapies equipped with combinatorial arming gene circuits to elicit broad and sustained anti-tumor immune responses. Senti is also developing next-generation cell therapies that more precisely target and eliminate cancer cells while sparing healthy tissue.

Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, and LifeForce Capital among its investors.

### **For General Inquiries**

Curt Herberts

CFO and CBO

650-906-1674

[press@senti.bio](mailto:press@senti.bio)

### **For Media Inquiries**

John Kang

309-310-4537

[senti.bio@hdmz.com](mailto:senti.bio@hdmz.com)